Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Chief Legal Officer | August 03, 2026 | August 05, 2026 |
| Dare Bioscience, Inc.CERU · Entity 7799 | VP, General Counsel | January 05, 2017 | January 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 100,000 · Balance 100,000 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date. F2: Includes 100,000 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2036-08-02 | Direct | 450,000 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 450,000 · Balance 450,000 F3: 25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.
F2: Includes 100,000 RSUs.
F3: 25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Dare Bioscience, Inc.
Report date January 05, 2017 · Filed January 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-04 | Direct | 50,000 |
Reported balance
After 2017-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-05 · Grant · Acquired 50,000 · Balance 50,000 F1: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-04 | Direct | 100,000 |
Reported balance
After 2017-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-05 · Grant · Acquired 100,000 · Balance 100,000 F2: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017.
F2: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 28,795 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 21,938 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 37,500 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.25 · Expires 2027-07-13 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 23,188 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-01 · Disposition to issuer · Disposed 13,586 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-01 · Disposition to issuer · Disposed 3,972 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.25 · Expires 2027-07-13 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-01 · Disposition to issuer · Disposed 35,312 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-10-01 · Disposition to issuer · Disposed 78,414 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-10-01 · Disposition to issuer · Disposed 71,028 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Mersana Therapeutics, Inc.
Report date January 06, 2026 · Filed January 06, 2026
Section 16 reporting ended · disclosed 2026-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 1
1 source rowRow 1 · 2026-01-06 · Other · Disposed 3,131 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-06 · Disposition to issuer · Disposed 3,047 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-06 · Disposition to issuer · Disposed 6,702 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $424.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-06 · Disposition to issuer · Disposed 4,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $157.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-06 · Disposition to issuer · Disposed 1,800 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $151.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-06 · Disposition to issuer · Disposed 1,527 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $151.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-06 · Disposition to issuer · Disposed 4,922 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-06 · Disposition to issuer · Disposed 1,078 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.50 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-06 · Disposition to issuer · Disposed 7,921 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-01-06 · Disposition to issuer · Disposed 100 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-01-06 · Disposition to issuer · Disposed 717 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-01-06 · Disposition to issuer · Disposed 1,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-01-06 · Disposition to issuer · Disposed 2,166 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),
F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.
F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 23:33 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001610717-26-000351 · form4.xml · derivative · entry 2 Carvajal Alejandra · CIK 0001645755 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2036-08-02 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 23:33 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000351 · form4.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date. F2 · balance_after: Includes 100,000 RSUs. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerRestricted Stock Units · Derivative | 2,166 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 13 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,166 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerRestricted Stock Units · Derivative | 1,500 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 12 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerRestricted Stock Units · Derivative | 717 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 11 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 717 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerRestricted Stock Units · Derivative | 100 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 10 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 7,921 | Not disclosed Strike: $75.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 9 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,921 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 1,078 | Not disclosed Strike: $75.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 8 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,078 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 4,922 | Not disclosed Strike: $151.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 7 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,922 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 1,527 | Not disclosed Strike: $151.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 6 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,527 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 1,800 | Not disclosed Strike: $157.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 5 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,800 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 4,500 | Not disclosed Strike: $424.50 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 4 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 6,702 | Not disclosed Strike: $16.01 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 3 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,702 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Disposition to issuerStock Option (right to buy) · Derivative | 3,047 | Not disclosed Strike: $16.01 | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · derivative · entry 2 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,047 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:51 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | OtherCommon Stock | 3,131 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-001380 · tm261736-9_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2 · price: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. Read SEC document |
| January 16, 2025 Filed Jan 18, 2025 00:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 5,096 | $0.58 | $2,955.68 |
DisclosureSEC source: 0001104659-25-004591 · tm253733-2_4seq1.xml · nonDerivative · entry 2 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,296 F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 22:23 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 952 | $0.63 | $599.76 |
DisclosureSEC source: 0001104659-25-004180 · tm253581-4_4seq1.xml · nonDerivative · entry 2 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,892 F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted Stock Unit · Derivative | 54,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004591 · tm253733-2_4seq1.xml · derivative · entry 5 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,167 Underlying: Common Stock · 54,167 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F7 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant. F7 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (Right to Buy) · Derivative | 243,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001104659-25-004591 · tm253733-2_4seq1.xml · derivative · entry 4 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 243,750 shares Expires 2035-01-14 F6 · derivative.exercise_date: The option shall vest in equal quarterly installments over four years from the date of grant. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004591 · tm253733-2_4seq1.xml · derivative · entry 3 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F5 · derivative.exercise_date: 25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years. F5 · derivative.expiration_date: 25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004591 · tm253733-2_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 15, 2024. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 02:17 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 3,330 | $0.66 | $2,197.80 |
DisclosureSEC source: 0001104659-25-003876 · tm253488-3_4seq1.xml · nonDerivative · entry 2 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,344 F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 22:23 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004180 · tm253581-4_4seq1.xml · derivative · entry 3 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: 25% of the total number of RSUs granted vested on January 14, 2025, and the remainder shall vest on January 14, 2026. F4 · derivative.expiration_date: 25% of the total number of RSUs granted vested on January 14, 2025, and the remainder shall vest on January 14, 2026. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 22:23 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004180 · tm253581-4_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 14, 2022. Read SEC document |
| January 13, 2025 Filed Jan 16, 2025 02:17 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 8,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003876 · tm253488-3_4seq1.xml · derivative · entry 3 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,917 Underlying: Common Stock · 8,958 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: 25% of the total number of RSUs granted vested on January 13, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years. F4 · derivative.expiration_date: 25% of the total number of RSUs granted vested on January 13, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years. Read SEC document |
| January 13, 2025 Filed Jan 16, 2025 02:17 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 8,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003876 · tm253488-3_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 21:48 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 5,598 | $1.96 | $10,972.08 |
DisclosureSEC source: 0001104659-24-106750 · tm2425739d4_4seq1.xml · nonDerivative · entry 3 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,716 F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.92 to $2.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 02, 2024 Filed Oct 7, 2024 21:48 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 8,089 | $2.00 | $16,178.00 |
DisclosureSEC source: 0001104659-24-106750 · tm2425739d4_4seq1.xml · nonDerivative · entry 2 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,314 F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.82 to $2.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 01, 2024 Filed Oct 7, 2024 21:48 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-106750 · tm2425739d4_4seq1.xml · derivative · entry 4 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F6 · derivative.exercise_date: Fully vested as of October 1, 2024. F6 · derivative.expiration_date: Fully vested as of October 1, 2024. Read SEC document |
| October 01, 2024 Filed Oct 7, 2024 21:48 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-106750 · tm2425739d4_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon vesting of the restricted stock units ("RSUs") awarded to the Reporting Person on September 5, 2023. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 22:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 4,381 | $2.71 | $11,872.51 |
DisclosureSEC source: 0001104659-24-004543 · tm243529-3_4seq1.xml · nonDerivative · entry 3 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,403 F3 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.70 to $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 22:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004543 · tm243529-3_4seq1.xml · derivative · entry 7 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F9 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant. F9 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant. Read SEC document |
| January 15, 2024 Filed Jan 17, 2024 22:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001104659-24-004543 · tm243529-3_4seq1.xml · derivative · entry 6 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2034-01-14 F8 · derivative.exercise_date: The option shall vest in equal quarterly installments over four years from the date of grant. Read SEC document |
| January 14, 2024 Filed Jan 17, 2024 22:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004543 · tm243529-3_4seq1.xml · derivative · entry 5 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F7 · derivative.exercise_date: 25% of the total number of RSUs granted vested on January 14, 2024, and the remainder shall vest thereafter in equal annual installments over the next two years. F7 · derivative.expiration_date: 25% of the total number of RSUs granted vested on January 14, 2024, and the remainder shall vest thereafter in equal annual installments over the next two years. Read SEC document |
| January 14, 2024 Filed Jan 17, 2024 22:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004543 · tm243529-3_4seq1.xml · nonDerivative · entry 2 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 14, 2022. Read SEC document |
| January 13, 2024 Filed Jan 17, 2024 22:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted Stock Unit · Derivative | 8,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004543 · tm243529-3_4seq1.xml · derivative · entry 4 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,875 Underlying: Common Stock · 8,958 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F6 · derivative.exercise_date: 25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years. F6 · derivative.expiration_date: 25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years. Read SEC document |
| January 13, 2024 Filed Jan 17, 2024 22:18 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 8,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004543 · tm243529-3_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 21:59 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted stock unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-099022 · tm2325674-6_4seq1.xml · derivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The RSUs will vest on October 1, 2024, subject to the Reporting Person's continued service to the Issuer on such vesting date. F2 · derivative.expiration_date: The RSUs will vest on October 1, 2024, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:15 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 3,944 | $3.89 | $15,342.16 |
DisclosureSEC source: 0001104659-23-052984 · tm2314135-1_4seq1.xml · nonDerivative · entry 2 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,326 F2 · kind: Pursuant to automatic sell-to-cover instructions adopted by the Reporting Person on April 26, 2021, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The automatic sale instructions for the sell-to-cover were intended to comply with the requirements of Rule 10b5-1(c). The sale was not a discretionary trade by the Reporting Person. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:15 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted stock unit · Derivative | 13,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-052984 · tm2314135-1_4seq1.xml · derivative · entry 3 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The RSUs vested as to 50% of the shares on April 26, 2022 and as to 50% of the shares on April 26, 2023. F4 · derivative.expiration_date: The RSUs vested as to 50% of the shares on April 26, 2022 and as to 50% of the shares on April 26, 2023. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:15 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 13,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-052984 · tm2314135-1_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on April 26, 2021. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 01:09 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 782 | $5.74 | $4,488.68 |
DisclosureSEC source: 0001104659-23-004736 · tm233833-1_4seq1.xml · nonDerivative · entry 2 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,020 F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.74 to $5.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 14, 2023 Filed Jan 19, 2023 01:09 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted stock unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004736 · tm233833-1_4seq1.xml · derivative · entry 5 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F7 · derivative.exercise_date: 25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years. F7 · derivative.expiration_date: 25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years. Read SEC document |
| January 14, 2023 Filed Jan 19, 2023 01:09 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004736 · tm233833-1_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 14, 2022. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 01:09 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted stock unit · Derivative | 35,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004736 · tm233833-1_4seq1.xml · derivative · entry 4 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,833 Underlying: Common Stock · 35,833 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F6 · derivative.exercise_date: The RSUs shall vest in equal annual installments over four years from the date of grant. F6 · derivative.expiration_date: The RSUs shall vest in equal annual installments over four years from the date of grant. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 01:09 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock option (right to buy) · Derivative | 161,250 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001104659-23-004736 · tm233833-1_4seq1.xml · derivative · entry 3 Carvajal Alejandra · CIK 0001645755 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,250 Underlying: Common Stock · 161,250 shares Expires 2033-01-12 F4 · derivative.exercise_date: The option shall vest in equal quarterly installments over four years from the date of grant. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 21:23 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionRestricted stock unit · Derivative | 13,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-052419 · tm2213920-1_4seq1.xml · derivative · entry 3 Carvajal Alejandra · CIK 0001645755 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,250 Underlying: Common Stock · 13,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The RSUs vested as to 50% of the shares on April 26, 2022 and will vest as to 50% of the shares on April 26, 2023, subject to the Reporting Person's continued service to the Issuer on such date. F4 · derivative.expiration_date: The RSUs vested as to 50% of the shares on April 26, 2022 and will vest as to 50% of the shares on April 26, 2023, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 21:23 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | SaleCommon Stock | 3,948 | $3.69 | $14,568.12 |
DisclosureSEC source: 0001104659-22-052419 · tm2213920-1_4seq1.xml · nonDerivative · entry 2 Carvajal Alejandra · CIK 0001645755 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,302 F2 · kind: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 21:23 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 13,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-052419 · tm2213920-1_4seq1.xml · nonDerivative · entry 1 Carvajal Alejandra · CIK 0001645755 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on April 26, 2021. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 22:43 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005540 · tm223926-1_4seq1.xml · derivative · entry 2 Carvajal Alejandra · CIK 0001645755 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 14, 2022. F3 · derivative.expiration_date: The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 14, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.